Description
Venetoclax-Azacitidine, the new standard of care for AML patients unfit for intensive treatment: A guide for clinical practice
Article: Venetoclax-Azacitidine, the new standard of care for AML patients unfit for intensive treatment: A guide for clinical practice
€3.03
Related products
-
Article: Highlights in genitourinary cancers
€3.03 Add to cart -
Article: Highlights in gynaecological cancers
€3.03 Add to cart -
Article: Calendar of events
€3.03 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart
